Drug intelligence / Profile preview

IAX35-Series

Development stage: Preclinical
Lead developer: InterAx Biotech
Modality: Small Molecules
Administration: Oral

Overview

The IAX35-Series is a preclinical-stage small molecule GIP receptor (GIP-R) antagonist being developed by InterAx Biotech. Designed for oral, once-daily administration, it is primarily targeted at treating obesity, type 2 diabetes (T2D), and sarcopenia. The compound is intended to be used in combination with GLP-1 receptor agonists, such as InterAx's IAX30-Series, to enhance weight management, improve tolerability by reducing gastrointestinal side effects, and prevent muscle loss (sarcopenia) during weight reduction. InterAx Biotech utilizes a proprietary platform combining machine learning and mathematical modeling of cellular processes to optimize these GPCR-targeted candidates.

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on IAX35-Series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IAX35-Series.

Explore the full profile